JAZZ vs OPY · P/E 1988, rev $4.07B vs P/E 13, rev $1.43B
Jazz Pharmaceuticals PLC (JAZZ) versus Oppenheimer Holdings Inc (OPY) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Oppenheimer Holdings Inc (OPY) is a capital markets company listed on NYSE.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported OPY revenue for 2024-12-31 was $1.43B. Net income was $71.2M. Revenue was up 14.7% from 2023-12-31 to 2024-12-31. OPY currently screens at market cap $1.15B and trailing P/E 12.8.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. OPY currently screens at market cap $1.15B and trailing P/E 12.8.
Not investment advice. Open the JAZZ and OPY stock pages for the full models.
Not investment advice.